Risk of serious infection, myocardial infarction, stroke, and thromboembolic events in patients in the United States with ulcerative colitis treated with tofacitinib compared with biologic treatments

Inflammatory Bowel Diseases · Published 2026-06-30 · DOI 10.1093/ibd/izag142

Free full text

Authors (15)

David T Rubin, Stefan Schreiber, Laurent Peyrin-Biroulet, Silvio Danese, Milena A Gianfrancesco, Arif Soonasra, Sarah Sidhu, Ivana Vranic, Ahmed Shelbaya, David Gruben, Yuqin Wei, Kevin L Winthrop, Jeffrey R Curtis, Miguel D Regueiro, Marla C Dubinsky

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Rubin, D., Schreiber, S., Peyrin-Biroulet, L., et al. (2026). Risk of serious infection, myocardial infarction, stroke, and thromboembolic events in patients in the United States with ulcerative colitis treated with tofacitinib compared with biologic treatments. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izag142

Related articles